Targeting Angiogenesis in Rheumatoid Arthritis: Mechanistic Insights, Therapeutic Advances and Nanomedicine Perspectives

Abstract

Angiogenesis is the process of formation of new blood vessels, a physiological process that becomes dysregulated in pathologic conditions, including autoimmune diseases. In rheumatoid arthritis, a prototypic autoimmune disorder characterized by chronic synovial inflammation and joint destruction, pathological angiogenesis plays a crucial role in sustaining inflammation, facilitating immune cell infiltration, and promoting pannus formation. This review synthesizes recent advances (2023-2025) in the understanding of the mechanisms driving angiogenesis in autoimmune diseases, with a focused lens on Rheumatoid Arthritis. The review explores structural and functional aberrations in Rheumatoid Arthritis synovial vasculature, key pro-angiogenic mediators including vascular endothelial growth factor and angiopoietins, and emerging signaling pathways including Notch and HIF-1α. Therapeutic strategies targeting angiogenesis-from conventional anti-VEGF agents to innovative nanomedicines and natural compounds-are reviewed, outlining clinical trial outcomes and challenges such as resistance and off-target effects. Through the integration of insights from stromal cell interactions, metabolic reprogramming, and epigenetic regulation, this article underlines the opportunity for disease modification in Rheumatoid Arthritis and broader autoimmune contexts through angiogenesis-targeted interventions. Future directions emphasize precision medicine approaches, including biomarker-driven therapies and combination regimens, to improve remission rates and quality of life.